September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A new method to determine correct Ruthenium-106 brachytherapy dose to ocular tumor apex using ultrasonography B-scan artifacts.
Author Affiliations & Notes
  • Jens F Kiilgaard
    Ophthalmology, Rigshospitalet, Copenhagen, Denmark
  • Charlotte Espensen
    Ophthalmology, Rigshospitalet, Copenhagen, Denmark
    Oncology, Rigshospitaet, Copenhagen, Denmark
  • Peter Koch Jensen
    Ophthalmology, Roskilde Hospital, Roskilde, Denmark
  • Lotte S Fog
    Oncology, Rigshospitaet, Copenhagen, Denmark
  • Kristian Klemp
    Ophthalmology, Rigshospitalet, Copenhagen, Denmark
  • Hans C. Fledelius
    Ophthalmology, Rigshospitalet, Copenhagen, Denmark
  • Lena Specht
    Oncology, Rigshospitaet, Copenhagen, Denmark
  • Footnotes
    Commercial Relationships   Jens Kiilgaard, None; Charlotte Espensen, None; Peter Jensen, None; Lotte Fog, None; Kristian Klemp, None; Hans Fledelius, None; Lena Specht, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4095. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jens F Kiilgaard, Charlotte Espensen, Peter Koch Jensen, Lotte S Fog, Kristian Klemp, Hans C. Fledelius, Lena Specht; A new method to determine correct Ruthenium-106 brachytherapy dose to ocular tumor apex using ultrasonography B-scan artifacts.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4095.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To present a new method using artifacts from ultrasonography B-scans to determine correct dose to apex of the tumor in patients treated with Ru-106 brachytherapy for intraocular tumors.

Methods : 273 eyes were included in the study and 245 (90 %) of these were evaluable. Tumor height and double dose depth were measured based on the mirror-image artifact associated with ultrasound. Distances from the plaque to the tumor base were calculated from these two measures. Minimum doses to apex of the tumor were determined using Plaque SimulatorTM.

Results : Distances from the plaque to tumor base were distributed with mean μ=0.99 (median: 1, range: 0.1 mm – 2.9 mm). In a phantom simulation study it showed that an increase in scleral thickness from 0.3 mm to 1.7 mm resulted in minimum dose delivered to the apex of the tumor ranged from 130-70 Gy. Provided a fully adapted plaque, ultrasound could be used to determine dose depth, by exploiting the mirror-image artifact.

Conclusions : We found that distances from the plaque to tumor base vary among patients. This distance must be accurately taken into account to ensure that the prescribed dose is delivered during Ru-106 treatments.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.